DNDi aims to:
- Make treatments safer, shorter, and more affordable and effective for all forms of leishmaniasis.
- In the short term, better treatment regiments are being developed using existing drugs.
- In the long term, the goal is to develop an entirely new generation of all-oral drugs.
The current portfolio for both visceral and cutaneous leishmaniasis includes:
For more details on each project, see DNDi‘s Global Portfolio